Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pp65-flLAMP RNA-pulsed dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The pp65-flLAMP RNA-pulsed dendritic cell vaccine is an autologous cellular immunotherapy designed to target glioblastoma multiforme (GBM). The vaccine consists of a patient's own dendritic cells (DCs) that have been loaded (pulsed) via electroporation with messenger RNA (mRNA) encoding the human cytomegalovirus (CMV) 65 kDa phosphoprotein (pp65). A critical feature of this construct is the fusion of the pp65 sequence to the full-length lysosomal-associated membrane protein (flLAMP) signal sequence. This fusion redirects the synthesized pp65 protein to the lysosomal compartment within the dendritic cell, which significantly enhances the presentation of pp65 peptides on MHC class II molecules in addition to MHC class I. This dual presentation is intended to provoke a robust and polyfunctional T-cell response, involving both CD4+ helper T cells and CD8+ cytotoxic T cells, against CMV antigens which are specifically expressed in GBM tumor cells but absent in the surrounding healthy brain tissue.
- Other names
- pp65-LAMP mRNA-pulsed dendritic cell vaccinepp-65-LAMP mRNA-pulsed dendritic cell vaccinepp 65-LAMP mRNA-pulsed dendritic cell vaccineCMV pp65-LAMP mRNA-loaded dendritic cell vaccinepp65-flLAMP mRNA-pulsed autologous dendritic cell vaccinepp-65-flLAMP mRNA-pulsed autologous dendritic cell vaccinepp 65-flLAMP mRNA-pulsed autologous dendritic cell vaccine
02
Targets
pp65 (Cytomegalovirus phosphoprotein 65)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on pp65-flLAMP RNA-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pp65-flLAMP RNA-pulsed dendritic cell vaccine.